Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

T-cell immunity key factor in reducing Covid-19 immunity: study 

A new study says that Covid-19 vaccines should elicit a broad immune response that includes antibodies, and the body's helper and killer T cells, in order to be effective.&nbsp;
The research, published in the journal Cell, confirms that a multi-layered, virus-specific immune response is important for controlling the novel coronavirus during the acute phase of the infection and reducing its disease severity.
A senior author from the study explains that as people age, the immune system's supply of deployable immature T cells dwindles, with fewer cells available to be activated to respond to a new virus, which looks to be one factor making older people drastically more susceptible to severe or fatal Covid-19.'&nbsp;
The scientists believe T cells, and helper T cells in particular, are associated with better protective immune responses.

Covid-19 vaccines must elicit broad immune response to work
Study confirms multi-layered immunity key to reducing Covid&nbsp;risk
Aging reduces the body's supply of T cells, dwindling immune response&nbsp;
Could be the reason why elderly are more susceptible to Covid

A new study says that Covid-19 vaccines should elicit a broad immune response that includes antibodies, and the body's helper and killer T cells, in order to be effective.&nbsp;
The research, published in the journal Cell, confirms that a multi-layered, virus-specific immune response is important for controlling the novel coronavirus during the acute phase of the infection and reducing its disease severity.
A senior author from the study explains that as people age, the immune system's supply of deployable immature T cells dwindles, with fewer cells available to be activated to respond to a new virus, which looks to be one factor making older people drastically more susceptible to severe or fatal Covid-19.'&nbsp;
The scientists believe T cells, and helper T cells in particular, are associated with better protective immune responses.

US scientists discover new drug that may prevent Covid-19 

A Covid-19 breakthrough? US medical team developing a drug that they claim could treat and prevent the spread of novel coronavirus&nbsp;

Pittsburgh scientists discover new drug that may prevent Covid-19 

Breakthrough? US scientists&nbsp;discover drug that may prevent Covid-19&nbsp;
Antibody-based drug effective on animals, human trials next
Scientists described the Ab8 treatment in the journal Cell&nbsp;
The drug could be released for public sometime in 2021&nbsp;
'It won't have any negative side-effects':&nbsp;UPMC&nbsp;doctors

In what is being touted as a breakthrough, researchers from the University of Pittsburgh, North Carolina among others say they are working on a drug that can prevent people from contracting Covid-19 as well as treat people who have been infected.&nbsp;
The Medical Center team said that they are yet to test the antibody-based drug on humans but the molecule has been 'highly effective' in preventing the virus in mice and hamsters.&nbsp;
Describing the potential treatment dubbed Ab8 in the journal Cell, researchers say the drug could be made available before the vaccine is released sometime in 2021.
Additionally, the UPMC&nbsp;doctors said this treatment 'won't have any negative side-effects in people,' which may not be true of a potential vaccine.&nbsp;

cell

Categories